Research Analysts Issue Forecasts for HURA Q2 Earnings

TuHURA Biosciences (NASDAQ:HURA) – Equities research analysts at Zacks Small Cap issued their Q2 2025 earnings per share estimates for shares of TuHURA Biosciences in a report released on Tuesday, February 4th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will earn ($0.09) per share for the quarter. Zacks Small Cap also issued estimates for TuHURA Biosciences’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.17) EPS and Q2 2026 earnings at ($0.17) EPS.

A number of other research analysts have also recently commented on HURA. Rodman & Renshaw assumed coverage on TuHURA Biosciences in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Maxim Group initiated coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They set a “buy” rating and a $15.00 target price for the company. Finally, RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th.

TuHURA Biosciences Stock Down 8.2 %

NASDAQ:HURA opened at $4.48 on Wednesday. TuHURA Biosciences has a 12 month low of $2.84 and a 12 month high of $14.60. The business’s 50 day moving average price is $4.80.

Hedge Funds Weigh In On TuHURA Biosciences

An institutional investor recently bought a new position in TuHURA Biosciences stock. Suncoast Equity Management bought a new stake in shares of TuHURA Biosciences (NASDAQ:HURA) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 102,997 shares of the company’s stock, valued at approximately $421,000. Suncoast Equity Management owned about 0.24% of TuHURA Biosciences as of its most recent filing with the SEC. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.